Should I buy or sell MacroGenics stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MGNX shares. View MGNX analyst ratings or view top-rated stocks .

What is MacroGenics' stock price target for 2024?

5 Wall Street research analysts have issued 1-year price objectives for MacroGenics' stock. Their MGNX share price targets range from $8.00 to $17.00. On average, they predict the company's share price to reach $11.83 in the next twelve months. This suggests a possible upside of 35.9% from the stock's current price. View analysts price targets for MGNX or view top-rated stocks among Wall Street analysts .

How have MGNX shares performed in 2023?

MacroGenics' stock was trading at $6.71 at the beginning of the year. Since then, MGNX shares have increased by 29.8% and is now trading at $8.71. View the best growth stocks for 2023 here .

When is MacroGenics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024. View our MGNX earnings forecast .

How were MacroGenics' earnings last quarter?

MacroGenics, Inc. (NASDAQ:MGNX) issued its earnings results on Monday, November, 6th. The biopharmaceutical company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.03) by $0.49. The biopharmaceutical company had revenue of $10.40 million for the quarter, compared to analysts' expectations of $54.80 million. MacroGenics had a net margin of 41.13% and a negative trailing twelve-month return on equity of 51.83%.

What ETF holds MacroGenics' stock ?

iShares Genomics Immunology and Healthcare ETF holds 221,160 shares of MGNX stock, representing 1.03% of its portfolio.

What is Scott Koenig's approval rating as MacroGenics' CEO?

12 employees have rated MacroGenics Chief Executive Officer Scott Koenig on Glassdoor.com . Scott Koenig has an approval rating of 89% among the company's employees.

What other stocks do shareholders of MacroGenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV) , Exelixis (EXEL) , Gilead Sciences (GILD) , NVIDIA (NVDA) , Micron Technology (MU) , Sangamo Therapeutics (SGMO) , Sorrento Therapeutics (SRNE) , Intra-Cellular Therapies (ITCI) , TG Therapeutics (TGTX) and Bausch Health Companies (BHC) .

Who are MacroGenics' major shareholders?

MacroGenics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Armistice Capital LLC (7.60%), Acadian Asset Management LLC (2.21%), Silverarc Capital Management LLC (2.04%), Rock Springs Capital Management LP (1.90%), Federated Hermes Inc. (1.50%) and Charles Schwab Investment Management Inc. (1.33%). Insiders that own company stock include Edward Hurwitz, Ezio Bonvini, James Karrels , Jeffrey Stuart Peters, Target N V Biotech and Thomas Spitznagel . View institutional ownership trends .

How do I buy shares of MacroGenics?

Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

MacroGenics Stock Price, News & Analysis (NASDAQ:MGNX)

$8.71

-0.22 (-2.46%)

(As of 12/8/2023 ET)

Compare

Today's Range: $8.66
▼
$9.10
50-Day Range: $4.48
▼
$8.93
52-Week Range: $4.29
▼
$9.10

Volume: 379,432 shs
Average Volume: 564,302 shs
Market Capitalization: $540.28 million

P/E Ratio: 10.89
Dividend Yield: N/A
Price Target: $11.83

MacroGenics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 35.9% Upside
$11.83 Price Target
Short Interest: Bearish
11.00% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.61
Upright™ Environmental Score
News Sentiment: 0.15
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$669,000 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.73) to ($1.85) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Medical Sector

151st out of 932 stocks

Pharmaceutical Preparations Industry

52nd out of 431 stocks

3.5

Analyst's Opinion

Consensus Rating
MacroGenics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.83, MacroGenics has a forecasted upside of 35.9% from its current price of $8.71.
Amount of Analyst Coverage
MacroGenics has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
11.00% of the float of MacroGenics has been sold short.
Short Interest Ratio / Days to Cover
MacroGenics has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.
Change versus previous month
Short interest in MacroGenics has recently decreased by 4.73%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
MacroGenics does not currently pay a dividend.
Dividend Growth
MacroGenics does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
MacroGenics has received a 66.61% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Monoclonal antibodies" and "Clinical research services for cancer" products. See details.
Environmental Sustainability
The Environmental Impact score for MacroGenics is -1.61.

2.9

News and Social Media Coverage

News Sentiment
MacroGenics has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for MacroGenics this week, compared to 1 article on an average week.
Search Interest
10 people have searched for MGNX on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
MarketBeat Follows
13 people have added MacroGenics to their MarketBeat watchlist in the last 30 days. This is an increase of 550% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MacroGenics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $669,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 10.00% of the stock of MacroGenics is held by insiders.
Percentage Held by Institutions
96.89% of the stock of MacroGenics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for MacroGenics are expected to decrease in the coming year, from ($1.73) to ($1.85) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of MacroGenics is 10.89, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 110.24.
Price to Earnings Ratio vs. Sector
The P/E ratio of MacroGenics is 10.89, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 107.63.
Price to Book Value per Share Ratio
MacroGenics has a P/B Ratio of 3.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About MacroGenics Stock (NASDAQ:MGNX)

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3;Retifanlimab, an monoclonal antibody used for cancer therapeutics; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

MGNX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MGNX Stock News Headlines

December 8, 2023 | seekingalpha.com

MacroGenics: This Top-Rated Stock Soars Big, But I'm Not Buying

December 6, 2023 | americanbankingnews.com

MacroGenics, Inc. (NASDAQ:MGNX) Given Average Rating of "Buy" by Analysts

December 10, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 30, 2023 | americanbankingnews.com

Reviewing MacroGenics (NASDAQ:MGNX) & Pfizer (NYSE:PFE)

November 26, 2023 | benzinga.com

Macrogenics Stock (NASDAQ:MGNX) Dividends: History, Yield and Dates

November 8, 2023 | msn.com

Guggenheim Upgrades Macrogenics (MGNX)

November 7, 2023 | finance.yahoo.com

MacroGenics (MGNX) Q3 2023 Earnings Call Transcript

November 7, 2023 | finance.yahoo.com

MacroGenics, Inc. (NASDAQ:MGNX) Q3 2023 Earnings Call Transcript

December 10, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 6, 2023 | msn.com

MacroGenics files for $300M mixed shelf

November 6, 2023 | sfgate.com

MacroGenics: Q3 Earnings Snapshot

November 6, 2023 | finance.yahoo.com

MacroGenics Provides Update on Corporate Progress and Third Quarter 2023 Financial Results

November 6, 2023 | finance.yahoo.com

Macrogenics Inc (MGNX) Reports Q3 2023 Earnings: Net Income of $17. ...

November 5, 2023 | markets.businessinsider.com

What Wall Street expects from Macrogenics's earnings

November 3, 2023 | benzinga.com

A Preview Of Macrogenics's Earnings

October 31, 2023 | finance.yahoo.com

MacroGenics Announces Date of Third Quarter 2023 Financial Results Conference Call

October 20, 2023 | markets.businessinsider.com

Promising Outlook for MacroGenics Based on Daiichi-Merck Partnership and Phase 2 Asset Development

September 5, 2023 | finance.yahoo.com

MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research Program

August 11, 2023 | msn.com

HC Wainwright & Co. Reiterates Macrogenics (MGNX) Buy Recommendation

August 11, 2023 | finance.yahoo.com

MacroGenics, Inc. (NASDAQ:MGNX) Q2 2023 Earnings Call Transcript

August 10, 2023 | finanznachrichten.de

MacroGenics, Inc.: MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results

August 10, 2023 | markets.businessinsider.com

BMO Capital Remains a Buy on MacroGenics (MGNX)

August 10, 2023 | markets.businessinsider.com

JMP Securities Sticks to Its Buy Rating for MacroGenics (MGNX)

August 9, 2023 | finance.yahoo.com

MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results

July 31, 2023 | finance.yahoo.com

MacroGenics Announces Date of Second Quarter 2023 Financial Results Conference Call

July 27, 2023 | finance.yahoo.com

MGNX - MacroGenics, Inc.

July 5, 2023 | finance.yahoo.com

MacroGenics (NASDAQ:MGNX) shareholders have endured a 83% loss from investing in the stock three years ago

See More Headlines

Receive MGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/06/2023
Today: 12/10/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/20/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MGNX
CUSIP: N/A
CIK: 1125345
Web: www.macrogenics.com
Phone: (301) 251-5172
Fax: 301-251-5321
Employees: 357
Year Founded: 2000

Price Target and Rating

Average Stock Price Target: $11.83
High Stock Price Target: $17.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +35.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.80
Trailing P/E Ratio: 10.89
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-119,760,000.00
Net Margins: 41.13%
Pretax Margin: 41.13%
Return on Equity: -51.83%
Return on Assets: -25.18%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.68
Quick Ratio: 5.66

Sales & Book Value

Annual Sales: $151.94 million
Price / Sales: 3.56
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.31 per share
Price / Book: 3.77

Miscellaneous

Outstanding Shares: 62,030,000
Free Float: 55,826,000
Market Cap: $540.28 million
Optionable: Optionable
Beta: 2.08

Social Links

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Scott Koenig M.D. (Age 71)
Ph.D., President, CEO & Director
Comp: $1.06M
Mr. James Karrels (Age 56)
Senior VP, CFO & Corporate Secretary
Comp: $626.83k
Mr. Eric Blasius Risser (Age 50)
Chief Operating Officer
Comp: $651.36k
Dr. Thomas M. Spitznagel Ph.D. (Age 56)
Senior Vice President of Technical Operations
Comp: $550.97k
Dr. Ezio Bonvini (Age 69)
Senior VP of Research & Chief Scientific Officer
Comp: $612.21k
Mr. Jeffrey Stuart Peters (Age 52)
Senior VP, General Counsel & Corporate Compliance Officer
Dr. Stephen L. Eck M.D. (Age 68)
Ph.D., Senior VP of Clinical Development & Chief Medical Officer
Comp: $577.62k
Ms. Lynn Cilinski (Age 65)
VP, Controller & Treasurer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MGNX Stock Analysis - Frequently Asked Questions

Should I buy or sell MacroGenics stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MGNX shares.
View MGNX analyst ratings or view top-rated stocks.
What is MacroGenics' stock price target for 2024?: 5 Wall Street research analysts have issued 1-year price objectives for MacroGenics' stock. Their MGNX share price targets range from $8.00 to $17.00. On average, they predict the company's share price to reach $11.83 in the next twelve months. This suggests a possible upside of 35.9% from the stock's current price.
View analysts price targets for MGNX or view top-rated stocks among Wall Street analysts.
How have MGNX shares performed in 2023?: MacroGenics' stock was trading at $6.71 at the beginning of the year. Since then, MGNX shares have increased by 29.8% and is now trading at $8.71.
View the best growth stocks for 2023 here.
When is MacroGenics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024.
View our MGNX earnings forecast.
How were MacroGenics' earnings last quarter?: MacroGenics, Inc. (NASDAQ:MGNX) issued its earnings results on Monday, November, 6th. The biopharmaceutical company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.03) by $0.49. The biopharmaceutical company had revenue of $10.40 million for the quarter, compared to analysts' expectations of $54.80 million. MacroGenics had a net margin of 41.13% and a negative trailing twelve-month return on equity of 51.83%.
What ETF holds MacroGenics' stock ?: iShares Genomics Immunology and Healthcare ETF holds 221,160 shares of MGNX stock, representing 1.03% of its portfolio.

What is Scott Koenig's approval rating as MacroGenics' CEO?: 12 employees have rated MacroGenics Chief Executive Officer Scott Koenig on Glassdoor.com. Scott Koenig has an approval rating of 89% among the company's employees.
What other stocks do shareholders of MacroGenics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), Intra-Cellular Therapies (ITCI), TG Therapeutics (TGTX) and Bausch Health Companies (BHC).
Who are MacroGenics' major shareholders?: MacroGenics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Armistice Capital LLC (7.60%), Acadian Asset Management LLC (2.21%), Silverarc Capital Management LLC (2.04%), Rock Springs Capital Management LP (1.90%), Federated Hermes Inc. (1.50%) and Charles Schwab Investment Management Inc. (1.33%). Insiders that own company stock include Edward Hurwitz, Ezio Bonvini, James Karrels, Jeffrey Stuart Peters, Target N V Biotech and Thomas Spitznagel.
View institutional ownership trends.
How do I buy shares of MacroGenics?: Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:MGNX) was last updated on 12/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial